Global Neuraminidase Inhibitor Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Neuraminidase Inhibitor Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Influenza viruses are characterized by two surface glycoproteins i.e. hemagglutinnin and neuraminidase. Neuraminidase are the antigens which play an important role in defining the particular strain of influenza. Dosage and safety of neuraminidase inhibitors are the two main parameters, affecting the growth of neuraminidase inhibitors market. The various symptoms of influenza are cough, running nose, fever, headache, fatigue, chills etc. The neuraminidase are recommended for the treatment of the symptoms after the forty eight hours of start of these symptoms.
There are few neuraminidase inhibitors, being sold in the market. The neuraminidase inhibitors have been classified as zenamivir, oseltamivir, peramivir, leninamivir and few other neuraminidase inhibitors. Zenamivir and oseltamivir are the neuraminidase inhibitors which are being used for the treatment of influenza A or influenza B.
Neuraminidase Inhibitor report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Neuraminidase Inhibitor market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Drug Stores are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Neuraminidase Inhibitor industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Neuraminidase Inhibitor key manufacturers include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, BioCryst and Daiichi Sankyo, etc. GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche are top 3 players and held % sales share in total in 2022.
Neuraminidase Inhibitor can be divided into Zanamivir, Oseltamivir, Peramivir and Laninamivir, etc. Zanamivir is the mainstream product in the market, accounting for % sales share globally in 2022.
Neuraminidase Inhibitor is widely used in various fields, such as Hospital Pharmacies, Drug Stores, Retail Stores and Others, etc. Hospital Pharmacies provides greatest supports to the Neuraminidase Inhibitor industry development. In 2022, global % sales of Neuraminidase Inhibitor went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neuraminidase Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo
Segment by Type
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Hospital Pharmacies
Drug Stores
Retail Stores
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Neuraminidase Inhibitor market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Neuraminidase Inhibitor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Neuraminidase Inhibitor industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Neuraminidase Inhibitor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Neuraminidase Inhibitor introduction, etc. Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Neuraminidase Inhibitor market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
There are few neuraminidase inhibitors, being sold in the market. The neuraminidase inhibitors have been classified as zenamivir, oseltamivir, peramivir, leninamivir and few other neuraminidase inhibitors. Zenamivir and oseltamivir are the neuraminidase inhibitors which are being used for the treatment of influenza A or influenza B.
Neuraminidase Inhibitor report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Neuraminidase Inhibitor market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Drug Stores are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Neuraminidase Inhibitor industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Neuraminidase Inhibitor key manufacturers include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, BioCryst and Daiichi Sankyo, etc. GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche are top 3 players and held % sales share in total in 2022.
Neuraminidase Inhibitor can be divided into Zanamivir, Oseltamivir, Peramivir and Laninamivir, etc. Zanamivir is the mainstream product in the market, accounting for % sales share globally in 2022.
Neuraminidase Inhibitor is widely used in various fields, such as Hospital Pharmacies, Drug Stores, Retail Stores and Others, etc. Hospital Pharmacies provides greatest supports to the Neuraminidase Inhibitor industry development. In 2022, global % sales of Neuraminidase Inhibitor went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neuraminidase Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo
Segment by Type
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Segment by Application
Hospital Pharmacies
Drug Stores
Retail Stores
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Neuraminidase Inhibitor market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Neuraminidase Inhibitor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Neuraminidase Inhibitor industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Neuraminidase Inhibitor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Neuraminidase Inhibitor introduction, etc. Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Neuraminidase Inhibitor market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices